Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 2/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341914 | 1.00 | PPARA (0.57) | PPARACTSSPPARGRAB9AKLK7 | |
| SCHEMBL7992987 | 0.83 | PPARA (0.57) | PPARACTSSPPARGRAB9AKLK7 | |
| SCHEMBL7992991 | 0.83 | PPARA (0.57) | PPARACTSSPPARGRAB9AKLK7 | |
| SCHEMBL9439194 | 0.81 | PPARA (0.62) | PPARACTSSPPARGRAB9AKLK7 | |
| SCHEMBL2909574 | 0.80 | SYK (0.45) | PPARACTSSUSP2L3MBTL1 | |
| SCHEMBL2910539 | 0.80 | SYK (0.45) | PPARACTSSUSP2L3MBTL1 | |
| SCHEMBL12528516 | 0.79 | USP2 (0.45) | PPARACTSSPPARGUSP2 | |
| SCHEMBL29229258 | 0.78 | PPARA (0.69) | PPARACTSSPPARGRAB9AKLK7 | |
| SCHEMBL8697793 | 0.78 | PPARA (0.65) | PPARACTSSPPARGRAB9AKLK7 | |
| SCHEMBL2728639 | 0.77 | PPARA (0.74) | PPARACTSSPPARGRAB9AKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2220055-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009010429-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | PPARA 708/4885CTSS 2548/4885PPARG 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.